Wearable Naloxone Device Rated More Acceptable Than Implant

Naloxone reverses an opioid overdose by displacing opioids from receptors in the brain. That is life-saving, and it is also abrupt. In a person who is physically dependent on opioids, a full naloxone dose can precipitate withdrawal within minutes, bringing on vomiting, agitation, muscle pain, sweating and severe distress.

This is the clinical reason overdose reversal and withdrawal management belong in the same discussion. Someone who survives a reversal is often in acute withdrawal and at high risk of using again quickly to relieve it.

Medically supervised detox and rapid access to medication for opioid use disorder are what turn a reversal into something durable. A device that administers naloxone automatically would produce that same precipitated withdrawal, which is part of why acceptability research on these devices is worth reading carefully.

What the Study Found

Researchers surveyed 60 people who use opioids and 126 people working in addiction treatment, asking them to rate a preclinical device designed to detect overdose-induced respiratory failure and administer naloxone. Participants rated two versions, wearable and implantable.

Acceptability was significantly higher for the wearable version in both groups. Among people who use opioids the difference was statistically significant, and among the treatment workforce the gap was larger still.

Within the group of people who use opioids, three subgroups rated the device as more acceptable: those with a history of overdose, those who had used medication for opioid use disorder, and those who used opioids intravenously. Those associations are correlational and drawn from a small sample, so they point toward hypotheses rather than conclusions.

Among workforce participants, higher acceptability was associated with less stigmatizing views of harm reduction. Demographic characteristics and workplace characteristics showed no significant association. The authors conclude that individual differences should be factored into further testing and any eventual rollout.

Understanding Naloxone and Medication for Opioid Use Disorder

Naloxone is an opioid antagonist. It occupies opioid receptors without activating them, restoring breathing within minutes. It has no effect on someone who has not taken opioids, and its effects can fade before the opioids clear, which is why medical monitoring after a reversal is standard.

Medication for opioid use disorder is a different category of drug and a different job. Buprenorphine, a partial agonist, and methadone, a full agonist, reduce withdrawal symptoms and cravings and are the evidence-based standard for treating opioid use disorder.

Naltrexone, an antagonist, is started only after withdrawal is complete. The finding that people with MOUD experience rated the naloxone device more favorably is notable, though this study cannot explain why.

Finding Medical Detox

Neither version of this device is available. It is preclinical, and this study measured whether people would accept it, not whether it works. Naloxone nasal spray, however, is available over the counter now, and having it on hand is the single most consequential thing a family can do.

Detox.com lists medically supervised detox centers with information on substances treated, levels of care, MOUD availability and accepted insurance, so you can find a program that can start buprenorphine or methadone rather than one that only manages symptoms. Call 800-996-6135(Sponsored) to speak with a treatment specialist today.